Hormonal prevention of prostate cancer

被引:12
作者
Brawley, OW [1 ]
机构
[1] Emory Univ, Winship Canc Ctr, Atlanta, GA 30322 USA
关键词
D O I
10.1016/S1078-1439(03)00004-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Prostate cancer is disease in which the mortality rate is highly variable among populations. An increasing risk with migratory changes suggests that some environmental factor or factors influence prostate cancer risk. It is well established that the prostate is hormonally influenced. Carcinogenesis is a process of malignant transformation evolving over time, involving cellular growth and division. There is evidence suggesting that androgenic influences over a period time encourages the process of prostate carcinogenesis. Studies of prostate biology support the concept that dihydrotestosterone is the principal androgen responsible for both normal and hyperplastic growth of the prostate gland. It may be that androgen causes prostate carcinogenesis. Suppression of dihydrotestosterone synthesis may inhibit carcinogenic transformation. Some preclinical and clinical observations support this hypothesis. A placebo controlled randomized trial using finasteride, an inhibitor of 5-alpha-reductase, the enzyme that converts testosterone to dihydrotestosterone, is ongoing. The endpoint of this trial is reduction of prostate cancer incidence. (C) 2003 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:67 / 72
页数:6
相关论文
共 53 条
[1]  
BERG JW, 1975, CANCER RES, V35, P3345
[2]  
BRAWLEY OW, 1994, CANCER EPIDEM BIOMAR, V3, P177
[3]   LATENT CARCINOMA OF PROSTATE AT AUTOPSY IN 7 AREAS - COLLABORATIVE STUDY ORGANIZED BY INTERNATIONAL-AGENCY-FOR-RESEARCH-ON-CANCER, LYONS, FRANCE [J].
BRESLOW, N ;
CHAN, CW ;
DHOM, G ;
DRURY, RAB ;
FRANKS, LM ;
GELLEI, B ;
LEE, YS ;
LUNDBERG, S ;
SPARKE, B ;
STERNBY, NH ;
TULINIUS, H .
INTERNATIONAL JOURNAL OF CANCER, 1977, 20 (05) :680-688
[4]   THE LENGTH AND LOCATION OF CAG TRINUCLEOTIDE REPEATS IN THE ANDROGEN RECEPTOR N-TERMINAL DOMAIN AFFECT TRANSACTIVATION FUNCTION [J].
CHAMBERLAIN, NL ;
DRIVER, ED ;
MIESFELD, RL .
NUCLEIC ACIDS RESEARCH, 1994, 22 (15) :3181-3186
[5]  
Debruyne Frans, 2002, Semin Urol Oncol, V20, P4, DOI 10.1053/suro.2002.35051
[6]  
Dorgan JP, 1998, CANCER EPIDEM BIOMAR, V7, P1069
[7]   Finasteride in the treatment of clinical benign prostatic hyperplasia: A systematic review of randomised trials [J].
Edwards J.E. ;
Moore R.A. .
BMC Urology, 2 (1) :1-17
[8]  
*EORTC, 1991, EORTC GEN GROUP MON, V10, P249
[9]  
Fears TR, 2002, CANCER EPIDEM BIOMAR, V11, P785
[10]   DESIGN OF THE PROSTATE-CANCER PREVENTION TRIAL (PCPT) [J].
FEIGL, P ;
BLUMENSTEIN, B ;
THOMPSON, I ;
CROWLEY, J ;
WOLF, M ;
KRAMER, BS ;
COLTMAN, CA ;
BRAWLEY, OW ;
FORD, LG .
CONTROLLED CLINICAL TRIALS, 1995, 16 (03) :150-163